Challenges of Doublet Therapies Approval and MRD-guided Treatment Decisions in CLL

Exploring the obstacles faced in gaining approval for doublet therapies in the US for CLL treatment, to address individual drug approval regulations. Insights from the FLAIR trial highlight the use of MRD status for treatment decisions, along with the efficacy of combining BTK inhibitors with anti-CD20 antibodies for improved undetectable MRD rates.